🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion

MK-9999-01B

Phase 2 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion for Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials